# Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

> **NCT03755739** · PHASE2,PHASE3 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Hepatocarcinoma
- Lung Cancer
- Melanoma
- Renal Cancer
- Head and Neck Cancer
- Pancreas Cancer
- Ovarian Cancer
- Colo-rectal Cancer
- Cervical Cancer
- Breast Cancer

## Interventions

- **DRUG:** Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy

## Key facts

- **NCT ID:** NCT03755739
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-01
- **Primary completion:** 2033-11-01
- **Final completion:** 2036-11-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755739, "Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03755739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*